A Phase 1 Study of KHN702 Tablets in Healthy Subjects

Phase 1 Not yet recruiting 84 enrolled Chengdu Kanghong Pharmaceutical Co., Ltd.

RandomizedSequentialTriple-blindTreatment

Summary

This study is a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) phase. The primary objective is to evaluate the safety and tolerability of KHN702 tablets in Chinese healthy volunteers（HVs).

Timeline

Start: 2025-06-21
Primary completion: 2026-04-01
Completion: 2026-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KHN702	Unknown	—	Oral

Indications

No indication recorded.